Security
Agenus Inc. Common Stock · AGEN
AGENNASDAQCommon stockCurrentCIK 1098972Updated Oct 6, 2026
Name history
ANTIGENICS INC /DE/ · through Jan 5, 2011
AGEN price & chart
Loading TradingView…
NASDAQ:AGEN on TradingView ↗About the company
Agenus is a clinical-stage immuno-oncology company advancing a pipeline of antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the population of patients who may benefit from immunotherapy. Founded in 1994, Agenus’ lead program is botensilimab plus balstilimab (BOT+BAL), a next-generation combination of a multifunctional, Fc-enhanced anti-CTLA-4 antibody and an anti-PD-1 antibody that has been evaluated in approximately 1,300 patients across nine tumor types.
In the news
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies News provided by Zydus Lifesciences Jun 03, 2025, 08:00 ET Share this article Share to X Share this article Share to X The acquisition will establis ↗
Recent filings
S-3 filing
S-8 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02
424B3 filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 233,891,000Source | 238,482,000Source | 172,692,000Source | 185,221,000Source | 292,415,000Source | 186,456,000Source | 200,201,000Source | 256,559,000Source | 226,798,000Source | 226,271,000Source | 313,913,000Source | 413,556,000Source |
| Property, Plant and Equipment, NetUSD | 15,987,000Source | 124,472,000Source | 14,322,000Source | 112,722,000Source | 127,569,000Source | 14,947,000Source | 117,030,000Source | 130,330,000Source | 15,470,000Source | 120,087,000Source | 133,421,000Source | 133,017,000Source |
| GoodwillUSD | 24,092,000Source | 24,694,000Source | 24,092,000Source | 24,092,000Source | 24,748,000Source | 24,092,000Source | 24,092,000Source | 24,698,000Source | 24,092,000Source | 24,092,000Source | 24,723,000Source | 25,467,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,122,000Source | 3,955,000Source | 2,880,000Source | 3,206,000Source | 4,136,000Source | 2,959,000Source | 3,291,000Source | 4,230,000Source | 3,037,000Source | 3,376,000Source | 4,411,000Source | 6,228,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,458,000Source | 44,784,000Source | 18,738,000Source | 9,534,000Source | 93,723,000Source | 34,996,000Source | 18,488,000Source | 52,856,000Source | 2,998,000Source | 40,437,000Source | 76,110,000Source | 178,674,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 538,000Source | 207,000Source | 14,725,000Source | 709,000Source | 719,000Source | 6,562,000Source | 354,000Source | 476,000Source | 1,831,000Source | 407,000Source | 25,836,000Source | 2,741,000Source |
| Assets, CurrentUSD | 133,950,000Source | 50,154,000Source | 78,810,000Source | 13,340,000Source | 100,004,000Source | 95,284,000Source | 23,138,000Source | 60,352,000Source | 133,436,000Source | 45,574,000Source | 112,416,000Source | 213,122,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,027,000Source | 28,612,000Source | 7,205,000Source | 26,421,000Source | 28,964,000Source | 7,458,000Source | 27,046,000Source | 29,340,000Source | 7,744,000Source | 27,308,000Source | 29,606,000Source | 31,269,000Source |
| Other Assets, NoncurrentUSD | 3,188,000Source | 6,595,000Source | 3,856,000Source | 5,440,000Source | 6,994,000Source | 3,013,000Source | 5,604,000Source | 7,609,000Source | 3,307,000Source | 5,834,000Source | 9,336,000Source | 4,453,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 329,000Source | 217,000Source | 427,000Source | 300,000Source | 211,000Source | 385,000Source | 266,000Source | 210,000Source | 353,000Source | 236,000Source | 3,944,000Source | 3,056,000Source |
| Additional Paid in CapitalUSD | 1,899,281,000Source | 1,845,815,000Source | 1,945,037,000Source | 1,882,704,000Source | 1,830,114,000Source | 1,922,370,000Source | 1,867,500,000Source | 1,816,985,000Source | 1,911,740,000Source | 1,857,662,000Source | 1,792,348,000Source | 1,644,658,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,172,187,000Source | -2,137,021,000Source | -2,144,089,000Source | -2,236,101,000Source | -2,070,635,000Source | -2,143,539,000Source | -2,208,146,000Source | -2,017,554,000Source | -2,182,765,000Source | -2,182,880,000Source | -1,955,668,000Source | -1,709,907,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,560,000Source | -1,347,000Source | -450,000Source | -1,504,000Source | -1,001,000Source | -437,000Source | -1,468,000Source | -1,071,000Source | -439,000Source | -1,398,000Source | -955,000Source | 915,000Source |
| Stockholders' Equity Attributable to ParentUSD | -274,137,000Source | -292,336,000Source | -199,075,000Source | -354,601,000Source | -241,311,000Source | -221,221,000Source | -341,848,000Source | -201,430,000Source | -271,111,000Source | -326,380,000Source | -160,331,000Source | -61,278,000Source |
| Liabilities and EquityUSD | 233,891,000Source | 238,482,000Source | 172,692,000Source | 185,221,000Source | 292,415,000Source | 186,456,000Source | 200,201,000Source | 256,559,000Source | 226,798,000Source | 226,271,000Source | 313,913,000Source | 413,556,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 287,132,000Source | 270,644,000Source | 231,820,000Source | 234,563,000Source | 270,666,000Source | 249,237,000Source | 208,304,000Source | 256,002,000Source | 323,489,000Source | 221,401,000Source | 255,897,000Source | 188,952,000Source |
| Operating Lease, Liability, CurrentUSD | 1,113,000Source | 2,427,000Source | 1,102,000Source | 2,496,000Source | 2,296,000Source | 1,054,000Source | 2,525,000Source | 2,811,000Source | 1,034,000Source | 2,446,000Source | 2,587,000Source | 1,943,000Source |
| Accounts Payable, CurrentUSD | 85,289,000Source | 45,899,000Source | 58,984,000Source | 74,396,000Source | 50,843,000Source | 71,084,000Source | 64,240,000Source | 50,693,000Source | 82,987,000Source | 61,470,000Source | 61,446,000Source | 40,939,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,383,000Source | 55,164,000Source | 9,538,000Source | 53,394,000Source | 55,786,000Source | 9,827,000Source | 53,982,000Source | 61,756,000Source | 10,108,000Source | 54,551,000Source | 62,511,000Source | 63,326,000Source |
| Other Liabilities, NoncurrentUSD | 376,000Source | 777,000Source | 247,000Source | 752,000Source | 1,490,000Source | 247,000Source | 761,000Source | 2,732,000Source | 259,000Source | 738,000Source | 5,420,000Source | 13,826,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -6,731,000Source | 20,532,000Source | -6,775,000Source | 18,293,000Source | 20,472,000Source | -6,762,000Source | 19,450,000Source | 11,107,000Source | -6,750,000Source | 19,956,000Source | 11,949,000Source | 6,376,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | — | — | — | — | 500,000Source | — | — | 800,000Source | — |
| Accrued Liabilities, CurrentUSD | 31,752,000Source | 36,695,000Source | 27,515,000Source | 39,311,000Source | 41,208,000Source | 36,987,000Source | 36,444,000Source | 41,291,000Source | 34,223,000Source | 34,961,000Source | 45,283,000Source | 38,259,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 3,500,000Source | 44,800,000Source | — | 9,500,000Source | 93,700,000Source | — | 18,500,000Source | 52,900,000Source | — | 40,400,000Source | 76,100,000Source | 193,400,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 112,000Source | 112,000Source | 112,000Source | 911,000Source |
| Long-term Debt, Current MaturitiesUSD | 10,610,000Source | 13,401,000Source | 30,068,000Source | 10,721,000Source | 13,425,000Source | 30,193,000Source | 731,000Source | 13,575,000Source | 44,655,000Source | 2,698,000Source | 146,000Source | 575,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 23,599,000Source | 0Source | — | 23,151,000Source | 0Source | — | 32,846,000Source | 0Source | 0Source | 30,473,000Source | 12,768,000Source | 12,584,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 14,684,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 63,911,000Source | -67,214,000Source | -567,000Source | -30,012,000Source | 39,206,000Source | -26,370,000Source | -3,083,000Source | -232,271,000Source | -257,437,042Source | -230,656,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,098,000Source | 3,482,000Source | 13,770,000Source | 17,390,000Source | 22,869,000Source | 18,337,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 4,731,000Source | -108,000Source | 1,728,000Source | -25,344,000Source | 23,461,000Source | -122,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -11,880,000Source | 2,642,000Source | 23,500,000Source | 2,013,000Source | 21,366,000Source | 6,494,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -35,950,000Source | -25,618,000Source | -77,195,000Source | -158,315,000Source | -224,202,000Source | -175,373,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 68,952,000Source | 57,000Source | 1,194,000Source | 27,000Source | 3,400,000Source | -33,610,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 5,000Source | 6,000Source | 576,000Source | 9,954,000Source | 53,062,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -993,000Source | 3,594,000Source | 36,593,000Source | 122,840,000Source | 119,866,000Source | 95,830,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 8,413,000Source | 2,500,000Source | 2,500,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 31,998,000Source | -21,949,000Source | -39,361,000Source | -35,708,000Source | -101,564,000Source | -113,257,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 188,000Source | 387,000Source | 1,175,000Source | 2,278,000Source | 3,168,000Source | 1,143,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,808,000Source | 9,280,000Source | 3,260,000Source | 3,441,000Source | 866,000Source | 3,333,000Source | 11,896,000Source | 27,327,000Source | 22,351,000Source | 18,238,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 300,000Source | 500,000Source | 1,500,000Source | 2,200,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 3,500,000Source | 44,800,000Source | — | 9,500,000Source | — | 18,500,000Source | — | 40,400,000Source | 76,100,000Source | 193,400,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 9,700,000Source | 12,800,000Source | 11,900,000Source | 4,700,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -200,000Source | -29,000Source | -100,000Source | -400,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | 0Source | 0Source | 40,379,000Source | 0Source | -937,000Source | -1,153,000Source | 1,408,000Source | 16,196,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | 5,300,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 10,860,000Source | 17,275,000Source | 8,466,000Source | 15,518,000Source | 6,860,000Source | 15,718,000Source | 54,392,000Source | 71,878,000Source | 78,739,000Source | 81,007,000Source |
| GoodwillUSD | — | — | 24,092,000Source | 24,694,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,723,000Source | 25,467,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 602,000Source | 0Source | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | 2,526,000Source | 0Source | -1,350,000Source | 0Source | -26,345,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 13,244,000Source | 36,748,000Source | 15,363,000Source | 13,343,000Source | 14,690,000Source | 12,983,000Source | 55,618,000Source | 120,421,000Source | — | — |
| Investment Income, InterestUSD | — | — | 74,000Source | 1,019,000Source | 121,000Source | 54,000Source | 21,000Source | 188,000Source | 345,000Source | 2,795,000Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -3,000Source | -828,000Source | -17,000Source | -2,057,000Source | -20,000Source | -1,104,000Source | -3,198,000Source | -5,059,000Source | -11,676,000Source | -10,582,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 63,860,000Source | -66,440,000Source | -604,000Source | -28,009,000Source | 39,172,000Source | -25,320,000Source | -101,000Source | -227,427,000Source | -245,974,000Source | -220,286,000Source |
| Nonoperating Income (Expense)USD | — | — | -19,298,000Source | 19,000Source | 856,000Source | -12,000Source | -208,000Source | -264,000Source | -2,220,000Source | 5,830,000Source | 37,000Source | 12,571,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 200,000Source | 900,000Source | — | 6,100,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 81,626,000Source | 19,000Source | 3,382,000Source | -12,000Source | 38,821,000Source | -264,000Source | 72,359,000Source | 5,830,000Source | — | — |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | -1,559,000Source | -93,000Source | -26,119,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 30,235,000Source | 25,112,000Source | 34,518,000Source | 25,691,000Source | 33,736,000Source | 24,066,000Source | 114,196,000Source | 103,463,000Source | 156,314,000Source | 98,024,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -4,545,000Source | -31,504,000Source | 11,293,000Source | -16,711,000Source | 15,054,000Source | -13,311,000Source | -20,169,000Source | -120,475,000Source | -159,549,000Source | -179,427,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 81,626,000Source | 19,000Source | 3,382,000Source | -12,000Source | 38,821,000Source | -264,000Source | 72,359,000Source | 5,830,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -3,083,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -3,000Source | -828,000Source | -17,000Source | -2,057,000Source | -20,000Source | -1,104,000Source | -3,198,000Source | -5,059,000Source | -11,676,000Source | -10,582,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 2Source | -3.08Source | -0.01Source | -1Source | 1.03Source | -1.03Source | 0Source | -10.59Source | -0.69Source | -0.78Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.94Source | -3.08Source | -0.01Source | -1Source | 1.02Source | -1.03Source | 0Source | -10.59Source | -0.69Source | -0.78Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 31,886,000Source | 21,550,000Source | 41,338,000Source | 28,117,000Source | 37,941,000Source | 24,469,000Source | 29,734,000Source | 21,473,000Source | 357,889Source | 281,743Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 32,858,000Source | 21,550,000Source | 41,338,000Source | 28,117,000Source | 38,285,000Source | 24,469,000Source | 29,734,000Source | 21,473,000Source | 357,889Source | 281,743Source |
| Interest Expense (non-operating)USD | — | — | 13,244,000Source | 36,748,000Source | 15,363,000Source | 13,343,000Source | 14,690,000Source | 12,983,000Source | 55,618,000Source | 120,421,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 300,000Source | 500,000Source | 1,500,000Source | 2,200,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 583,000Source | 3,203,000Source | 9,999,000Source | 13,343,000Source | 13,588,000Source | 6,946,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -200,000Source | -29,000Source | -100,000Source | -400,000Source |
| General and Administrative ExpenseUSD | — | — | 10,860,000Source | 17,275,000Source | 8,466,000Source | 15,518,000Source | 6,860,000Source | 15,718,000Source | 54,392,000Source | 71,878,000Source | 78,739,000Source | 81,007,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 602,000Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 6,620,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | 2,526,000Source | 0Source | -1,350,000Source | 0Source | -26,345,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -13,170,000Source | -35,729,000Source | -15,242,000Source | -13,289,000Source | -14,669,000Source | -12,795,000Source | -55,273,000Source | -117,626,000Source | -97,925,000Source | -61,863,000Source |
| Investment Income, InterestUSD | — | — | 74,000Source | 1,019,000Source | 121,000Source | 54,000Source | 21,000Source | 188,000Source | 345,000Source | 2,795,000Source | — | — |
| Labor and Related ExpenseUSD | — | — | 9,294,000Source | 15,283,000Source | 4,136,000Source | 11,327,000Source | 6,895,000Source | 12,105,000Source | 39,664,000Source | 61,814,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 63,860,000Source | -66,440,000Source | -604,000Source | -28,009,000Source | 39,172,000Source | -25,320,000Source | -101,000Source | -227,427,000Source | -245,974,000Source | -220,286,000Source |
| Nonoperating Income (Expense)USD | — | — | -19,298,000Source | 19,000Source | 856,000Source | -12,000Source | -208,000Source | -264,000Source | -2,220,000Source | 5,830,000Source | 37,000Source | 12,571,000Source |
| Other Cost and Expense, OperatingUSD | — | — | 5,464,000Source | 6,756,000Source | 3,407,000Source | 8,355,000Source | 945,000Source | 6,250,000Source | 24,488,000Source | 28,441,000Source | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 54,000Source | 54,000Source | 54,000Source | 54,000Source | 54,000Source | 54,000Source | 216,000Source | 215,000Source | 213,000Source | 212,000Source |
| Research and Development ExpenseUSD | — | — | 23,596,000Source | 41,058,000Source | 14,759,000Source | 26,710,000Source | 11,822,000Source | 21,522,000Source | 79,338,000Source | 155,528,000Source | 234,569,000Source | 186,691,000Source |
| Costs and Expenses | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298893
Registration 333-298111
Registration 333-297556
Filing attachments
agen-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 agen-ex99_1.htm EX-99.1 EX-99.1 FOR IMMEDIATE RELEASE Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer • Previously announced oversubscribed $85 million private placement, with up to $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution • ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more …
Read attachment ↗d111026dex41.htm · 8-K · 2026-07-13
EX-4.1 2 d111026dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUC…
Read attachment ↗d111026dex42.htm · 8-K · 2026-07-13
EX-4.2 3 d111026dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO TH…
Read attachment ↗d111026dex43.htm · 8-K · 2026-07-13
EX-4.3 4 d111026dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO TH…
Read attachment ↗d111026dex991.htm · 8-K · 2026-07-13
EX-99.1 7 d111026dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer $85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus’ registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer …
Read attachment ↗d111026dex992.htm · 8-K · 2026-07-13
EX-99.2 8 d111026dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Neoadjuvant BOT+BAL in MSS Colon Cancer Agenus PIPE Financing Announcement July 13, 2026 Agenus Speakers Garo H. Armen, PhD Robin Taylor, PhD Steven O’Day, MD Zack Armen Founder, Chairman & CEO Chief Commercial Officer Chief Medical Officer VP, Corporate Dev & IR 2 Industry Thought Leaders Professor Myriam Chalabi, MD Pashtoon Kasi, MD, MS Medical Oncologist Medical Oncologist Netherlands Cancer Institute, Amsterdam NL Rad Family Ch…
Read attachment ↗